Literature DB >> 8095513

Role of leukocyte adhesion molecules in complement-induced lung injury.

M S Mulligan1, C W Smith, D C Anderson, R F Todd, M Miyasaka, T Tamatani, T B Issekutz, P A Ward.   

Abstract

The bolus i.v. infusion of cobra venom factor into rats results in acute lung injury that is neutrophil-dependent, oxygen radical-mediated, and requires CD18. In our studies a more precise definition regarding the role of beta-integrins and requirements for cytokines was obtained by the use of blocking antibodies. Lung injury was quantitated by changes in permeability (leakage of 125I-BSA) and hemorrhage (extravasation of 51Cr-RBC). In animals treated with anti-CD11a, the permeability and hemorrhage parameters were reduced by 30 and 29%, respectively. Treatment with anti-CD11b resulted in reductions in permeability and hemorrhage by 53 and 48%, respectively, whereas anti-intercellular adhesion molecule-1 reduced the parameters of injury by 60 and 75%, respectively. Not surprisingly, treatment with antibodies to very late Ag-4, TNF-alpha and IL-1 failed to show any protective effects, which contrasts to the requirements for these molecules in lung injury after deposition of IgG immune complexes. Protective interventions were associated with a reduction in lung content of myeloperoxidase. These studies indicate that, in the cobra venom factor model of acute lung injury in rats, engagement of Mac-1, lymphocyte function-associated Ag-1, and intercellular adhesion molecule-1 are essential, whereas, in contrast to other models of neutrophil mediated lung injury, cytokines (TNF-alpha and IL-1) and very late Ag-4 are not required for the full development of injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095513

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  The pathophysiologic role of alpha 4 integrins in vivo.

Authors:  R R Lobb; M E Hemler
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

2.  Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells.

Authors:  K E Foreman; M M Glovsky; R L Warner; S J Horvath; P A Ward
Journal:  Inflammation       Date:  1996-02       Impact factor: 4.092

3.  Rous-Whipple Award Lecture. Role of complement in lung inflammatory injury.

Authors:  P A Ward
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

Review 4.  Mechanisms of the adult respiratory distress syndrome: selectins.

Authors:  R K Albert
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

Review 5.  Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin.

Authors:  S Tamraz; T Arrhenius; A Chiem; M J Forrest; F C Gaeta; Y B He; J Lei; A Maewal; M L Phillips; L W Vollger
Journal:  Springer Semin Immunopathol       Date:  1995

6.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Mary Allen Engle Award: The glue of life--a career retrospective.

Authors:  Robert F Todd
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

8.  Preservation of complement-induced lung injury in mice with deficiency of NADPH oxidase.

Authors:  H Kubo; D Morgenstern; W M Quinian; P A Ward; M C Dinauer; C M Doerschuk
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 9.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment.

Authors:  S M Wahl; J B Allen; K L Hines; T Imamichi; A M Wahl; L T Furcht; J B McCarthy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.